News Feature | Published:

Fresh from the biotech pipeline—2018

The FDA approved record numbers of new molecular entities, orphan drugs, small-molecule generics and biosimilars in 2018. Could industry’s regulatory success of the past two years become the new normal?

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Author information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark
Fig. 1: 2018 FDA approvals.
Fig. 2: 2018 NME approvals by therapeutic class.
Fig. 3: 2018 NME approvals by company category.
Fig. 4: Biosimilar approvals in the US.